The capacity of the BraE10-5 monoclonal antibody (mAb), with specificity for the Brucella spp. M epitope, to confer protection against infection with B. abortus 2308 (A-dominant strain) has been evaluated. Injected before infection, the BraE10-5 mAb diminished the bacterial counts in spleen from week 1 to week 8 postinfection and in liver from week 4 to week 7. Thus, protection mediated by the BmE10-5 mAb, as measured by a reduction in the bacterial counts in both spleen and liver, was demonstrated from week 2 to week 8 postinfection. The humoral immune response of IgG, IgM, IgG1 and IgG3 antibodies, specific against the B. abortus 2308 smooth lipopolysaccharide, was clearly suppressed in all the mice protected with the BraE10-5 mAb, thus demonstrating the importance, in protecting against infection, of the existence in serum of M-epitope-specific antibodies at the same time the infection is acquired. The development of subcellular vaccines including the Brucella M epitope could constitute an interesting alternative to attenuated living vaccines.
Introduction
Microorganisms belonging to the genus Brucella are facultative intracellular parasites that cause brucellosis in animals and man. Studies conducted to improve knowledge of the mechanisms inducing protection against brucellosis have demonstrated, in the mouse model, that both humoral [1] [2] [3] [4] [5] [6] [7] and cell-mediated (both CD4 + and CD8 + T cells subsets) [8, 9] immune responses * Corresponding author. Tel.: (23) 294 532. Fax: (23) 294 515. participate in protective immunity. The identification of Brucella spp. antigens with capacity to elicit protective immunity constitutes an aspect of great interest for the development of efficient subcellular vaccines, avoiding the disadvantages of those made from living attenuated bacteria, among them, underlying infections in animals [10] and humans [11] , and interference of the antibodies generated with the interpretation of serodiagnostic tests [12] .
Antibodies with specificity for the Brucella spp. smooth lipopolysaccharide (S-LPS) [5, 6] and specially those O-polysaccharide-specific [1] [2] [3] [4] 7] have been demonstrated, in the mouse model, to play 134 a crucial role in protective immunity. Brucella spp. O-polysaccharide bears two distinct antigens designated A and M [13] [14] [15] whose structures have been defined with nuclear magnetic resonance techniques [14, 16] . These antigens have been found to exist in all smooth Brucella strains at variable ratios defining the A-or M-dominant character of each strain [17] . Recently, the nature of three distinct epitopes on the Brucella spp. O-polysaccharide chain has been described: the M epitope, mainly expressed in the M antigen but also present in low quantities in the A antigen; the A epitope, expressed in the A antigen; and a common epitope of the A and M antigens [13] .
It has been suggested that the protection against Brucella spp. infection conferred by passively transferred polyclonal antisera or monoclonal antibodies [1] [2] [3] [4] [6] [7] [8] [9] would be due to an increased ingestion and intracellular killing of the microorganisms in phagocytic cells [7] . Monoclonal antibodies (mAb) with specificity for the A epitope have been shown to confer protection in mice against infection by Brucella strains bearing the homologous A antigenic determinant as the major epitope on the O-polysaccharide chain [1, 2] . However, little is known at present about the role that antibodies directed against minor epitopes present on the O-polysaccharide chain play in protection against infection and how the passively transferred antibodies may affect the humoral immune response generated against Brucella spp. infection.
Materials and Methods

Mice
Female CD-1 mice (Charles River, Barcelona, Spain) were purchased at 9 weeks of age and held for 1 week before use.
Bacterial strain and culture medium
Brucella abortus 2308 was used as the challenge strain. Virulent B. abortus 2308 was passaged in CD-1 mice and isolated in pure culture from spleens. Stock cultures were prepared from 72 h growth at 37°C on tryptic soy broth (TSB; BBL Microbiology Systems, Cockeysville, MD) enriched with 0.3% yeast extract (Difco Laboratories, Detroit, MI) and stored at -70°C in 50% glycerol. For infection experiments the contents of freshly thawed vials were cultured on tryptic soy agar (TSA; BBL Microbiology Systems) for 72 h at 37°C in a 5% CO 2 atmosphere. The cells were suspended in sterile phosphate-buffered saline (PBS) and adjusted turbidimetrically to the desired concentration. The exact dose was established retrospectively by viable counts.
Monoclonal antibody
The hybridoma line secreting the BmE10-5 mAb was obtained by fusing cells of the X63-Ag8.653 myeloma cell line (Bio-Rad Laboratories, Richmond, CA) with splenic B lymphocytes from BALB/c mice immunized with heat-killed cells of B. melitensis 16M [18] . Characterization of the BmE10-5 mAb was established previously by immunodiffusion techniques, indirect and competitive inhibition ELISA, and coagglutination tests [18, 19] . This monoclonal antibody, belonging to the IgG3 subclass, showed specificity against the M-epitope of the Brucella spp. Opolysaccharide antigen.
Ascitic fluid containing the BmE10-5 mAb was obtained from the peritoneal cavity of BALB/c mice primed with PRISTANE (Sigma Chemical Co., St. Louis, MO) before inoculation of the hybrid cells [18] . Passive protection experiments were performed with ascitic fluid diluted 1/4 in PBS and filter sterilized.
Passice transfer experiments
Mice were given 0.1 ml of the BmE10-5 mAb (ascitic fluid diluted 1/4 in PBS) through the tail vein 2 h 30 min before intravenous (i.v.) infection with 1.23 × 105 colony forming units (CFU) of B. abortus 2308 in 0.1 ml PBS. The infection protocol for control mice was the same but the mAb was substituted by PBS and the infection dose was 1.31 × 105 CFU.
Groups of five mice were killed by cervical dislocation at 1-week intervals postinfection (p.i.) and the spleen and the left lateral lobe of the liver were removed, homogenized in 10 ml of PBS, serially diluted and plated in triplicate on TSA. After 72 h of incubation in a 5% CO 2 atmosphere, CFU were counted and expressed by the log10 per organ value.
Blood samples were obtained weekly after infection from the tail vein for examination by indirect ELISA for antibodies. Serum samples were stored at -20°C until use.
Enzyme immunoassay
Indirect ELISA was used to analyze the anti-S-LPS antibody levels in the serum of control and antibody-treated mice. The assays were performed as described previously [20] . Purified S-LPS from B. abortus 2308 (1 p.g ml-1 in carbonate buffer, pH 9.6) [18] was used as the antigen adsorbed on 96-well microplates (Bioreba, Basel, Switzerland). Serum samples obtained from 5 mice of each group were pooled and double serial dilutions in phosphate buffer (pH 7.2) were added to the wells. Horseradish peroxidase-conjugated antibodies with anti-mouse-IgM, IgG, IgG1, IgG2a, IgG2b or lgG3-specificity (Nordic Immunological Laboratories, Tilburg, The Netherlands) were employed at 1/2500 dilution. OPhenylenediamine (Sigma) in phosphate-citrate buffer (pH 5) was used as substrate. Absorbance readings were made at 492 nm on an SLTLabinstruments EAR 400 FT. As negative controls, pooled sera obtained from 5 non-infected mice were used. Titers were expressed as the reciprocals of the highest sera dilution giving an absorbance 0.1 units greater than those obtained with the negative control sera after 10 rain of substrate incubation (negative control absorbance: 0.25).
Statistical methods
A mean value for each bacterial count was obtained by averaging the triplicate values following log10 conversion. Liver counts were adjusted considering that only the left lateral lobe was cultured (one-third of the organ [7] ), multiplying accordingly. The detection limits were 13 colonies per spleen and 39 per liver (1 CFU in one of the triplicates where 250/.d of the total 10 ml of the organ homogenate were cultured). Thus, when no CFU was detected in any of the triplicates, spleen and liver were considered to contain 12 and 38 CFU, respectively. Results are expressed as mean 135 log ~0 bacterial counts of 5 mice _+ standard deviation. Statistical significance was determined by Student's t test [21] .
Results
Passiue protection experiments
The capacity of the BraE10-5 mAb to confer protection in CD-1 mice against B. abortus 2308 i.v. infection was evaluated by comparing the long-term evolution of the bacterial numbers in spleen and liver in mice of two established groups. The first group of mice (control mice) received 0.1 ml PBS 2 h 30 rain before challenge with 1.31 x 105 CFU and the second (antibody-treated mice) was injected with the BraE10-5 mAb (0.1 ml ascitic fluid diluted 1/4 in PBS) 2 h 30 rain before infection with 1.23 X 105 CFU.
A significant reduction in the bacterial counts in spleen was observed in mice of both groups from week 1 p.i. to week 3 p.i. (P < 0.01), when the number of organisms reached a plateau (Table 1). However, the number of B. abortus 2308 cells recovered from spleen was significantly (P < 0.05 to P < 0.00l) lower (about 1 log10) in the antibody-treated mice than in the control group at each time point tested (1, 2, 3, 4, 6, 7 and 8 weeks p.i.) (Table 1) .
In liver, the number of organisms in the control mice decreased, to a higher extent than in spleen, from week 1 postchallenge to week 3 (P < 0.01) and remained almost invariable after this time (Table 1) . A similar pattern of infection evolution was observed for antibody-treated mice with a decrease in the bacterial counts from week 1 to week 4 p.i. when the number of B. abortus 2308 cells reached a plateau phase. Although the number of organisms isolated from liver was slightly higher in the antibody-treated mice than in the control mice at 1 week p.i. (P<0.05) (Table 1) , the BraE10-5 mAb fostered a reduction in bacterial counts at and after 4 weeks p.i., the number of organisms recovered from liver of the antibody-treated mice being significantly lower (P < 0.05 to P < 0.01) than those obtained in the control mice at 4, 6 and 7 weeks postchallenge (Table 1) . c In comparisons with untreated control group: *** P < 0.001; * * P < 0.01; * P < 0.05; NS, not significant.
Differences in antibody levels between the control and antibody-treated mice were also evident when IgM-class antibodies were determined. In non-protected mice, the highest antibody levels were obtained from week 3 to week 6 p.i. (titer of 1280), thereafter decreasing to a level of 640 (Fig. 1B) . By contrast, the titers of IgM-class antibodies never exceeded a value of 160 in mice protected with the BmE10-5 mAb (Fig. 1B) . 
Week postinfection
When considering bacterial counts isolated in spleen and liver jointly, no significant differences between both control and antibody-treated mice were observed at 1 week p.i. However, from week 2 to week 8 p.i., protection mediated by the BmE10-5 mAb was statistically significant (P < 0.05 to P < 0.001).
Effect of the BmEIO-5 m.Ab on the humoral immune response against the B. abortus 2308 S-LPS antigen
IgG-class antibodies with specificity for the B. abortus S-LPS antigen gave titers, in non-protected mice, lower than 20 at 1 and 2 weeks postchallenge, but after week 3 p.i. titers were progressively increased, reaching levels of 5120 at 8 weeks p.i. (Fig. 1A) . By contrast, IgG titers were always lower than 160 in mice protected with the BmE10-5 mAb (Fig. 1A) . longing to IgG3 subclass increased progressively after 3 weeks p.i. in the control mice, reaching the maximum value (titer of 2560) at 8 weeks p.i. (Fig. 2B) . Although the titers of IgG3 antibodies were higher in protected mice than in the controis from week 1 to week 3 p.i., the antibodytreated mice showed lower antibody levels (maximum of 320) than those detected in the non-protected mice after week 4 p.i. (Fig. 2B) . Finally, antibodies belonging to the IgG2a and IgG2b subclasses, with specificity for the B. abortus 2308 S-LPS, were nearly negligible in both control and protected mice. []). Infection patterns are described in Table 1 . Serum was recovered from 5 mice, pooled and tested in indirect ELISA with the B. abortus 2308 S-LPS as antigen. Fig. 2 shows the evolution of IgG1 and IgG3 antibodies with specificity for the B. abortus 2308 S-LPS in both groups of mice. In the non-protected mice, IgG1 antibodies were negligible until week 4 p.i., but from week 6 to week 8 p.i. titers reached levels of 2560 ( Fig. 2A) . By contrast, titers of IgG1 antibodies were always lower than 80 in the antibody-treated mice. Antibodies be-
Discussion
The capacity of the BmE10-5 mAb to confer protection in CD-1 mice against B. abortus 2308 infection was evaluated by measuring the reduction, in comparison with control mice, of bacterial numbers in spleen and liver, organs where the microorganisms are mainly localized after intravenous infection [22] .
Administered intravenously 2 h 30 min before infection, the BmE10-5 mAb decreased bacterial counts in spleen from 1 to 8 weeks p.i. (Table 1) . However, liver counts were slightly higher in the antibody-treated mice than in the controls at 1 week p.i. (Table 1) , although bacterial counts were significantly lower in the antibody-treated mice at and after 4 weeks p.i. (Table 1 ). It is probable that the reduction in splenic infection in the antibody-treated mice be due to the preferential localization of the opsonized microorganisms in the liver during the first stages of infection [6] .
On considering the bacterial counts recovered from spleen and liver together, the BmE10-5 mAb, with specificity for the Brucella spp. M epitope, has the ability to confer protection, at and after 2 weeks p.i., against infection by B. abortus 2308, a strain that expresses the M antigenic determinant as a minor epitope on the O-polysaccharide. By contrast, results obtained by other authors [1] , although disclosing the protection conferred by an A-specific mAb against the A-dominant B. abortus 544 and by an Mspecific mAb against the M-dominant B. meliten-sis H38, have failed to demonstrate the capacity of an M-epitope-specific mAb to confer protection, measured by a reduction of the bacterial counts in spleen, in BALB/c mice against infection with B. abortus 544 (A-dominant strain); this has been attributed to the poor binding of this mAb to the whole A-dominant bacteria. However, the BmE10-5 mAb used in the present study, although specific for the B. abortus 2308 minor epitope, has shown a significant titer, by indirect ELISA, against the Brucella A-dominant S-LPS [18] . Thus, the results described here demonstrate that protective immunity against Brucella is not only mediated by antibodies with specificity for the major epitope on the O-polysaccharide chain. Antibodies directed against the minor epitope with appropriate affinity can be efficient in reducing the infection level, a reduction that may be also influenced by the effect of the antibody subclass on the capacity of macrophages to capture the opsonized bacteria [1] .
It has been demonstrated that as result of the inoculation of the BmE10-5 mAb before infection, IgM and IgG class and IgG1 and IgG3 subclass anti-S-LPS antibody levels are diminished ( Figs. 1 and 2 ). The only exception to this effect was that in the protected mice the IgG3 subclass anti-S-LPS-specific antibody titers were higher than those in the control mice from 1 to 3 weeks p.i. (Fig. 2B) . This is probably due to residual levels of the passively transferred BmE10-5 mAb (belonging to IgG3 subclass) which, as seen in previous experiments, may persist in the sera of non-infected mice until week 4 postinoculation (data not shown).
The immunosuppressive effect observed in protected mice can be related to an inhibition of the humoral immune response mediated by the existence of circulating antigen-antibody complexes [23] [24] [25] . However, the possibility cannot be excluded that the BraE10-5 mAb may block structural or conformational epitopes essential for the immunogenicity of the S-LPS antigen.
In spite of the suppressive effect on the humoral response specific for the S-LPS, an immunodominant antigen in the smooth Brucella strains [20] , protection mediated by the BraE10-5 mAb was observed at and after week 2 p.i. However, although an important anti-S-LPS-antibody response was detected in non-protected mice, bacterial counts were higher in this group of mice than those observed in protected mice. This fact may mean that when anti-S-LPS antibodies are produced at high levels in non-protected mice (week 4 p.i.) the microorganisms are less accessible to antibodies. By contrast, the BraE10-5 mAb exists in serum when mice are infected and hence bacterial opsonization may be produced efficiently, improving bacterial clearance [6] . Nevertheless, in spite of the reduction in bacterial counts observed in mice protected with the BmE10-5 mAb until week 8 p.i., further experiments should be carried out to study how the low anti-S-LPS antibody levels in protected mice may affect, in a longer term infection, the evolution of bacterial numbers.
Additionally, spleen and liver counts decreased in both the control and antibody-treated mice from week 1 p.i. to week 3 p.i. in spleen and week 4 p.i in liver (Table 1) . These results suggest that not only the antibodies induced after infection in control mice or passively transferred in antibody-treated mice participate in protective immunity, but also that the cell-mediated immune response plays an important role in protecting against infection by the B. abortus 2308 facultative intracellular bacterium.
The results described in this paper demonstrate the importance, for the control of the infectious process, of the existence of M-epitopespecific antibodies in serum at the same time as the Brucella spp. infection is acquired. The administration, in animals or humans at high risk of contracting Brucella spp. infection, of vaccines that afford high levels of M-epitope-specific antibodies at the time of the contact with the microorganism would be of great practical importance in the design of new strategies directed to the control and eradication of brucellosis.
